{"id":961,"date":"2023-11-10T19:00:00","date_gmt":"2023-11-10T11:00:00","guid":{"rendered":"https:\/\/wingor.abvnet.com\/%e5%86%8d%e4%bc%a0%e4%bd%b3%e9%9f%b3%ef%bc%81%e8%8c%b5%e5%86%a0%e7%94%9f%e7%89%a9%e7%ac%ac%e5%9b%9b%e6%ac%be%e5%b9%b2%e7%bb%86%e8%83%9e%e6%96%b0%e8%8d%afind%e8%8e%b7%e5%8f%97%e7%90%86%ef%bc%81\/"},"modified":"2026-05-27T21:41:21","modified_gmt":"2026-05-27T13:41:21","slug":"%e5%86%8d%e4%bc%a0%e4%bd%b3%e9%9f%b3%ef%bc%81%e8%8c%b5%e5%86%a0%e7%94%9f%e7%89%a9%e7%ac%ac%e5%9b%9b%e6%ac%be%e5%b9%b2%e7%bb%86%e8%83%9e%e6%96%b0%e8%8d%afind%e8%8e%b7%e5%8f%97%e7%90%86%ef%bc%81","status":"publish","type":"post","link":"https:\/\/wingor.net\/en\/news\/%e5%86%8d%e4%bc%a0%e4%bd%b3%e9%9f%b3%ef%bc%81%e8%8c%b5%e5%86%a0%e7%94%9f%e7%89%a9%e7%ac%ac%e5%9b%9b%e6%ac%be%e5%b9%b2%e7%bb%86%e8%83%9e%e6%96%b0%e8%8d%afind%e8%8e%b7%e5%8f%97%e7%90%86%ef%bc%81\/","title":{"rendered":"More good news! Yinguan Biotech's fourth stem cell drug IND application has been accepted!"},"content":{"rendered":"
<\/p>\n
\n
\n
\n
\n

\u5386\u7ecf4\u5e74\u6253\u78e8\uff0c\u56fd\u5185\u6eb6\u7624\u75c5\u6bd2\u9886\u57df\u6700\u5927IP\u91cd\u78c5\u6765\u88ad\uff01<\/strong><\/span><\/p>\n

COVC 2023 \u7b2c\u56db\u5c4a\u6eb6\u7624\u75c5\u6bd2\u836f\u7269\u5f00\u53d1\u5927\u4f1a<\/span><\/strong><\/span>\u643a\u624b<\/span>30+<\/span><\/strong>\u4e1a\u5185\u9876\u5c16\u5168\u7403<\/span>\u6eb6\u7624\u75c5\u6bd2\u836f\u7269\u5f00\u53d1\u79d1\u5b66\u5bb6\u4e0e<\/span><\/span>1000+<\/span><\/strong><\/span>\u6765\u81ea\u6eb6\u7624\u75c5\u6bd2\u6838\u5fc3\u4f01\u4e1a\u53ca\u4ea7\u4e1a\u4e0a\u4e0b\u6e38\u4e13\u4e1a\u4eba\u58eb\uff0c<\/span>11\u670817-18\u65e5<\/span><\/strong><\/span>\u4e0e\u60a8\u5171\u805a\u4e0a\u6d77\uff01<\/span><\/span><\/p>\n

<\/span><\/span><\/a><\/p>\n

\u6765\u6e90\uff1a\u8335\u51a0\u751f\u7269<\/span><\/p>\n

\n
\n

\u8ddd\u79bb\u4e0a\u4e00\u6b3e\u5e72\u7ec6\u80de\u65b0\u836fIND\u83b7\u53d7\u7406\u4ec5\u4ec5\u8fc7\u53bb9\u5929\uff0c2023\u5e7411\u670810\u65e5\uff0c\u636e\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u836f\u7269\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u5b98\u7f51\u663e\u793a\uff0c\u6df1\u5733\u5e02\u8335\u51a0\u751f\u7269\u79d1\u6280\u6709\u9650\u516c\u53f8\u81ea\u4e3b\u7814\u53d1\u7684\u2160\u7c7b\u751f\u7269\u5236\u54c1\u201c\u4eba\u8110\u5e26\u95f4\u5145\u8d28\u5e72\u7ec6\u80de\u6ce8\u5c04\u6db2\u201d\u7684\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c (IND)\u7533\u8bf7\uff0c\u83b7\u5f97\u53d7\u7406\uff08\u53d7\u7406\u53f7\uff1aCXSL2300770\uff09\u3002<\/span><\/p>\n<\/section>\n

\u63a5\u8fde\u4e09\u6b3e\u5e72\u7ec6\u80de\u65b0\u836fIND\u5728\u4e00\u4e2a\u534a\u6708\u5185\u83b7\u5f97\u53d7\u7406\uff0c\u8335\u51a0\u751f\u7269\u7684\u5e72\u7ec6\u80de\u79d1\u7814\u521b\u65b0\u6210\u679c\u5448\u73b0\u201c\u4e95\u55b7\u5f0f\u201d\u589e\u957f\u3002\u622a\u81f3\u76ee\u524d\uff0c\u8335\u51a0\u751f\u7269\u5df2\u67094\u6b3e\u5e72\u7ec6\u80de\u65b0\u836fIND\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\uff0c\u5176\u4e2d1\u6b3e\u5e72\u7ec6\u80de\u65b0\u836f\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u9ed8\u793a\u8bb8\u53ef\u3002<\/span><\/p>\n

<\/p>\n

\u25b2CDE\u5b98\u7f51\uff1a\u8335\u51a0\u751f\u7269\u201c\u4eba\u8110\u5e26\u95f4\u5145\u8d28\u5e72\u7ec6\u80de\u6ce8\u5c04\u6db2\u201dIND\u7533\u8bf7\u53d7\u7406\u516c\u793a<\/span><\/p>\n

\u8335\u51a0\u751f\u7269\u4ee5\u4e34\u5e8a\u4ef7\u503c\u4e3a\u5bfc\u5411\uff08Clinical value\uff09\uff0c\u521b\u65b0\uff08innovation\uff09\u5f00\u53d1\u9ad8\u786e\u5b9a\u6027\uff08certainty\uff09\u7684\u65b0\u578b\u751f\u7269\u533b\u836f\u4ea7\u54c1\uff0c\u6253\u9020\u5e72\u7ec6\u80de\u5e73\u53f0\u3001\u5916\u6ccc\u4f53\u5e73\u53f0\u548c\u201c\u57fa\u56e0\u5de5\u7a0b+\u201d\u4e09\u5927\u6280\u672f\u5e73\u53f0\uff0c\u73b0\u6709\u5341\u4f59\u6761\u521b\u65b0\u751f\u7269\u533b\u836f\u7814\u53d1\u7ba1\u7ebf\u6b63\u5728\u5168\u901f\u63a8\u8fdb\u3002\u56e2\u961f\u59cb\u7ec8\u6000\u63e3\u9ad8\u6807\u51c6\u3001\u9ad8\u8981\u6c42\u3001\u9ad8\u8d28\u91cf\u7684\u7406\u5ff5\uff0c\u4ee5\u786c\u6838\u6280\u672f\u548c\u7a33\u5065\u59ff\u6001\uff0c\u52a9\u529b\u4e2d\u56fd\u751f\u7269\u533b\u836f\u4ea7\u4e1a\u5b9e\u73b0\u8de8\u8d8a\u5f0f\u53d1\u5c55\uff0c\u4e3a\u4eba\u7c7b\u5065\u5eb7\u4fdd\u9a7e\u62a4\u822a\u3002<\/span><\/p>\n

<\/p>\n<\/section>\n

\n
\n
\n
\n
\u514d\u8d23\u58f0\u660e\uff1a<\/span><\/strong><\/span>\u6587\u7ae0\u5185\u5bb9\u4ec5\u4f9b\u53c2\u8003\uff0c\u4e0d\u6784\u6210\u6295\u8d44\u5efa\u8bae\u3002\u672c\u516c\u4f17\u53f7\u53d1\u5e03\u7684\u5404<\/span><\/span>\u7c7b\u6587\u7ae0\u91cd\u5728\u5206\u4eab\uff0c\u5982\u6709\u4fb5\u6743\u8bf7\u8054\u7cfb\u6211\u4eec\uff0c\u6211\u4eec\u5c06\u4f1a\u5220\u9664\u3002<\/span><\/span><\/p>\n
<\/section>\n<\/section>\n
\n
\n
\n
\n
\n
\n
\n
<\/span><\/a><\/section>\n
\n

<\/span>\u3010COVC 2023 \u7b2c\u56db\u5c4a\u6eb6\u7624\u75c5\u6bd2\u836f\u7269\u5f00\u53d1\u5927\u4f1a\u3011<\/strong><\/span>\u643a\u624b30+\u4e1a\u5185\u9876\u5c16\u5168\u7403\u6eb6\u7624\u75c5\u6bd2\u836f\u7269\u5f00\u53d1\u79d1\u5b66\u5bb6\u3001\u4f01\u4e1a\uff0c\u4ee5\u53ca\u751f\u7269\u533b\u836f\u4ea7\u4e1a\u54a8\u8be2\u673a\u6784\u7ec4\u7ec7\uff0c\u5171\u540c\u63a2\u8ba8\u6eb6\u7624\u75c5\u6bd2\u836f\u7269\u672a\u6765\u53d1\u5c55\u4e0e\u7a81\u7834\u3001\u521b\u65b0\u836f\u7269\u7814\u53d1\uff0c\u63a8\u52a8\u6eb6\u7624\u7597\u6cd5\u7684\u4e34\u5e8a\u8f6c\u5316\uff0c\u8ba9\u5148\u8fdb\u7597\u6cd5\u66f4\u65e9\u60e0\u53ca\u60a3\u8005\u3002<\/span><\/span><\/span><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/section>\n
\n
\n
\n
\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n

\u62a5\u540d\u706b\u70ed\u8fdb\u884c\u4e2d\uff0c\u626b\u7801\u7acb\u5373\u54a8\u8be2\uff01<\/strong><\/span>\u8d5e\u52a9\u5f62\u5f0f\u5305\u62ec\u4f46\u4e0d\u4ec5\u9650\u4e8e\u6f14\u8bb2\u5e2d\u4f4d\u3001\u4f1a\u573a\u5c55\u4f4d\u3001\u4f1a\u520a\u5f69\u9875\u3001\u665a\u5bb4\u8d5e\u52a9\u3001\u4f1a\u8bae\u7528\u54c1\u5ba3\u4f20\u7b49\u3002<\/strong><\/span><\/p>\n

\u7535\u8bdd\uff1a13816031174\uff08\u540c\u5fae\u4fe1\uff09<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u5386\u7ecf4\u5e74\u6253\u78e8\uff0c\u56fd\u5185\u6eb6\u7624\u75c5\u6bd2\u9886\u57df\u6700\u5927IP\u91cd\u78c5\u6765\u88ad\uff01 COVC 2023 \u7b2c\u56db\u5c4a\u6eb6\u7624\u75c5\u6bd2\u836f\u7269\u5f00\u53d1\u5927\u4f1a\u643a\u624b30+\u4e1a\u5185… Read More »More good news! Yinguan Biotech's fourth stem cell drug IND application has been accepted!<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":962,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[37],"tags":[],"class_list":["post-961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gsdt"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t